MCM
ARQT icon

Moore Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Moore Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$186K – 508
2024
Q3 		$186K Hold
20,000
– – ﹤0.01% 390
2024
Q2 		$186K Hold
20,000
– – ﹤0.01% 376
2024
Q1 		$198K Buy
+20,000
New +$149K ﹤0.01% 354

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Moore Capital Management's ARQT Position: Q4 2024 in Review

Moore Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 20,000 shares — an estimated $186K sold.

Moore Capital Management first reported a position in ARQT in Q1 2024 and held it in 3 quarters. The position peaked at $198K in Q1 2024. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Moore Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Moore Capital Management sold 20,000 Arcutis Biotherapeutics shares in Q4 2024, an estimated $186K.
  • Moore Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 3 quarters.
  • Moore Capital Management's Arcutis Biotherapeutics position peaked at $198K in Q1 2024.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Moore Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.